GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Shiller PE Ratio

Diamyd Medical AB (OSTO:DMYD B) Shiller PE Ratio : (As of Jul. 24, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diamyd Medical AB Shiller PE Ratio Historical Data

The historical data trend for Diamyd Medical AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Shiller PE Ratio Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diamyd Medical AB's Shiller PE Ratio

For the Biotechnology subindustry, Diamyd Medical AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Shiller PE Ratio falls into.


;
;

Diamyd Medical AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Diamyd Medical AB's E10 for the quarter that ended in May. 2025 is calculated as:

For example, Diamyd Medical AB's adjusted earnings per share data for the three months ended in May. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of May. 2025 (Change)*Current CPI (May. 2025)
=-0.4/132.8245*132.8245
=-0.400

Current CPI (May. 2025) = 132.8245.

Diamyd Medical AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201508 -0.240 99.829 -0.319
201511 -0.153 100.129 -0.203
201602 -0.171 100.253 -0.227
201605 -0.684 100.914 -0.900
201608 -0.139 100.968 -0.183
201611 -0.097 101.517 -0.127
201702 -0.171 102.037 -0.223
201705 -0.292 102.679 -0.378
201708 -0.097 103.138 -0.125
201711 -0.194 103.413 -0.249
201802 -0.194 103.678 -0.249
201805 -0.194 104.632 -0.246
201808 -0.197 105.197 -0.249
201811 -0.194 105.443 -0.244
201902 -0.194 105.641 -0.244
201905 -0.097 106.895 -0.121
201908 -0.137 106.716 -0.171
201911 -0.097 107.345 -0.120
202002 0.486 106.742 0.605
202005 -0.097 106.882 -0.121
202008 -0.194 107.571 -0.240
202011 1.458 107.549 1.801
202102 0.194 108.190 0.238
202105 -0.486 108.838 -0.593
202108 -0.389 109.780 -0.471
202111 -0.486 111.069 -0.581
202202 -0.097 112.834 -0.114
202205 -0.194 116.746 -0.221
202208 -0.583 120.573 -0.642
202211 -0.389 123.803 -0.417
202302 -0.299 126.321 -0.314
202305 -0.299 128.034 -0.310
202308 -0.498 129.560 -0.511
202311 -0.398 130.958 -0.404
202402 -0.300 132.046 -0.302
202405 -0.400 132.818 -0.400
202408 -0.493 132.052 -0.496
202411 -0.398 133.000 -0.397
202502 -0.400 133.744 -0.397
202505 -0.400 132.825 -0.400

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diamyd Medical AB  (OSTO:DMYD B) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Diamyd Medical AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines